Evidence map›Paper›PMID 36304004›Full record

ArticleFrontiers in reproductive health2021

Synthetic Cannabinoid Agonist WIN 55212-2 Targets Proliferation, Angiogenesis, and Apoptosis

Harshavardhan Lingegowda, Jessica E Miller, Ryan M Marks, Lindsey K Symons, Taylor Alward, Alan E Lomax, Madhuri Koti, Chandrakant Tayade

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in reproductive health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Harshavardhan LingegowdaDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Jessica E MillerDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Ryan M MarksDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Lindsey K SymonsDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Taylor AlwardGastrointestinal Disease Research Unit (GIDRU), Queen's University, Kingston, ON, Canada.
Alan E LomaxGastrointestinal Disease Research Unit (GIDRU), Queen's University, Kingston, ON, Canada.
Madhuri KotiDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Chandrakant TayadeDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Queen's University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometriosis (EM) is characterized by the growth of endometrium-like tissue outside the uterus, leading to chronic inflammation and pelvic pain. Lesion proliferation, vascularization, and associated inflammation are the hallmark features of EM lesions. The legalization of recreational cannabinoids has garnered interest in the patient community and is contributing to a greater incidence of self medication; however, it remains unknown if cannabinoids possess marked disease-modifying properties. In this study, we assess the effects of synthetic cannabinoid, WIN 55212-2 (WIN 55), in EM-representative

Indexed as

angiogenesisapoptosiscannabinoidsendometriosisinflammation

Identifiers

PMID36304004
PMCPMC9580784
OpenAlexW3202684981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.